ChromaDex Corporation (CDXC): Price and Financial Metrics


ChromaDex Corporation (CDXC): $6.23

-0.53 (-7.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CDXC to Watchlist
Sign Up

Industry: Chemicals


Ranked

of 93

in industry

CDXC POWR Grades


  • Quality is the dimension where CDXC ranks best; there it ranks ahead of 64.95% of US stocks.
  • The strongest trend for CDXC is in Sentiment, which has been heading down over the past 48 weeks.
  • CDXC's current lowest rank is in the Sentiment metric (where it is better than 23.82% of US stocks).

CDXC Stock Summary

  • With a one year PEG ratio of 233, ChromaDex Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 88.05% of US stocks.
  • For CDXC, its debt to operating expenses ratio is greater than that reported by just 9.92% of US equities we're observing.
  • With a year-over-year growth in debt of 166.92%, ChromaDex Corp's debt growth rate surpasses 94.49% of about US stocks.
  • Stocks that are quantitatively similar to CDXC, based on their financial statements, market capitalization, and price volatility, are HAYN, HROW, NAOV, SREV, and KRKR.
  • Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to www.chromadex.com.

CDXC Valuation Summary

  • In comparison to the median Healthcare stock, CDXC's price/sales ratio is 17.18% lower, now standing at 9.4.
  • Over the past 150 months, CDXC's EV/EBIT ratio has gone down 20.7.
  • Over the past 150 months, CDXC's price/earnings ratio has gone down 21.9.

Below are key valuation metrics over time for CDXC.

Stock Date P/S P/B P/E EV/EBIT
CDXC 2021-08-31 9.4 13.8 -25.0 -23.6
CDXC 2021-08-30 9.1 13.4 -24.3 -22.8
CDXC 2021-08-27 9.3 13.6 -24.7 -23.2
CDXC 2021-08-26 9.0 13.3 -24.0 -22.6
CDXC 2021-08-25 8.9 13.1 -23.7 -22.3
CDXC 2021-08-24 8.9 13.1 -23.8 -22.3

CDXC Growth Metrics

  • The 5 year net cashflow from operations growth rate now stands at -1404.16%.
  • Its 3 year cash and equivalents growth rate is now at 532.79%.
  • The 5 year revenue growth rate now stands at 131.07%.
Over the past 33 months, CDXC's revenue has gone up $31,986,164.

The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 62.007 -17.123 -23.259
2021-03-31 59.595 -10.784 -21.404
2020-12-31 59.257 -10.6 -19.925
2020-09-30 56.901 -11.232 -22.681
2020-06-30 54.774 -15.147 -25.668
2020-03-31 50.588 -22.612 -29.712

CDXC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXC has a Quality Grade of C, ranking ahead of 64.95% of graded US stocks.
  • CDXC's asset turnover comes in at 1.178 -- ranking 15th of 677 Pharmaceutical Products stocks.
  • CEMI, MYGN, and NEOG are the stocks whose asset turnover ratios are most correlated with CDXC.

The table below shows CDXC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.178 0.612 -2.751
2021-03-31 1.276 0.607 -3.100
2020-12-31 1.545 0.595 -2.616
2020-09-30 1.466 0.586 -2.883
2020-06-30 1.361 0.577 -2.841
2020-03-31 1.237 0.569 -2.891

CDXC Price Target

For more insight on analysts targets of CDXC, see our CDXC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.80 Average Broker Recommendation 1.3 (Strong Buy)

CDXC Stock Price Chart Interactive Chart >

Price chart for CDXC

CDXC Price/Volume Stats

Current price $6.23 52-week high $23.66
Prev. close $6.76 52-week low $3.82
Day low $6.22 Volume 273,921
Day high $6.83 Avg. volume 1,648,598
50-day MA $8.08 Dividend yield N/A
200-day MA $8.09 Market Cap 424.87M

ChromaDex Corporation (CDXC) Company Bio


ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.


CDXC Latest News Stream


Event/Time News Detail
Loading, please wait...

CDXC Latest Social Stream


Loading social stream, please wait...

View Full CDXC Social Stream

Latest CDXC News From Around the Web

Below are the latest news stories about ChromaDex Corp that investors may wish to consider to help them evaluate CDXC as an investment opportunity.

ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #nicotinamideriboside--ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or NR) in various health outcomes. Through the industry-leading ChromaDex External Research Program (CERP), ChromaDex supplies Niagen® to researchers around the world at no cost to help advance the understanding of NRs impact on various age-related health cond

Business Wire | September 20, 2021

ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)

LOS ANGELES, September 20, 2021--ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or "NR") in various health outcomes. Through the industry-leading ChromaDex External Research Program (CERP™), ChromaDex supplies Niagen® to researchers around the world at no cost to help advance the understanding of NR’s impact on various age-related health co

Yahoo | September 20, 2021

Why Are ChromaDex Shares Trading Lower On Wednesday?

Full story available on Benzinga.com

Benzinga | September 15, 2021

Why ChromaDex Stock Is Sinking Today

What happened ChromaDex (NASDAQ: CDXC) took investors on a really wild ride on Wednesday. Shares of the global bioscience company fell as much as 26% before reversing course to eke out a small gain. But that gain was only temporary, and ChromaDex shares closed the day 4.

Yahoo | September 15, 2021

ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit

LOS ANGELES, September 15, 2021--ChromaDex Corp. (NASDAQ:CDXC) issued the following statement:

Yahoo | September 15, 2021

Read More 'CDXC' Stories Here

CDXC Price Returns

1-mo -26.01%
3-mo -36.82%
6-mo -35.71%
1-year 52.70%
3-year 45.22%
5-year 111.90%
YTD 29.79%
2020 11.37%
2019 25.66%
2018 -41.67%
2017 77.64%
2016 -9.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.973 seconds.